Brief: EQL Pharma Q4 EBIT SEK 5.1 Mln

EQL Pharma AB

08/05/2026 06:14

May 8 (Reuters) - EQL Pharma AB EQL.ST:

EQL PHARMA Q4 REVENUE SEK 120.2 MILLION

EQL PHARMA Q4 EBIT SEK 5.1 MILLION

SALES GROWTH REMAINS BELOW LONG-TERM TARGET OF 30%

EBITDA MARGIN OF 10% FALLS SHORT OF FIVE-YEAR PLAN TARGET OF 25%, MAINLY DUE TO SUPPLY SHORTAGES AND ONE-OFF EFFECTS

LONG-TERM TARGETS REMAIN UNCHANGED.

Source text: ID:nWkrhX4WH

Further company coverage: EQL.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;))